

Review

Open Access

Hereditary chronic pancreatitis

Jonas Rosendahl, Hans Bödeker, Joachim Mössner and Niels Teich*

Address: Medizinische Klinik und Poliklinik II, Universität Leipzig, Germany

Email: Jonas Rosendahl - jonas.rosendahl@medizin.uni-leipzig.de; Hans Bödeker - hans.boedeker@medizin.uni-leipzig.de;

Joachim Mössner - joachim.moessner@medizin.uni-leipzig.de; Niels Teich* - niels.teich@medizin.uni-leipzig.de

* Corresponding author

Published: 04 January 2007

Received: 25 November 2006

Orphanet Journal of Rare Diseases 2007, **2**:1 doi:10.1186/1750-1172-2-1

Accepted: 04 January 2007

This article is available from: <http://www.OJRD.com/content/2/1/1>

© 2007 Rosendahl et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Hereditary chronic pancreatitis (HCP) is a very rare form of early onset chronic pancreatitis. With the exception of the young age at diagnosis and a slower progression, the clinical course, morphological features and laboratory findings of HCP do not differ from those of patients with alcoholic chronic pancreatitis. As well, diagnostic criteria and treatment of HCP resemble that of chronic pancreatitis of other causes. The clinical presentation is highly variable and includes chronic abdominal pain, impairment of endocrine and exocrine pancreatic function, nausea and vomiting, maldigestion, diabetes, pseudocysts, bile duct and duodenal obstruction, and rarely pancreatic cancer. Fortunately, most patients have a mild disease. Mutations in the PRSS1 gene, encoding cationic trypsinogen, play a causative role in chronic pancreatitis. It has been shown that the PRSS1 mutations increase autocatalytic conversion of trypsinogen to active trypsin, and thus probably cause premature, intrapancreatic trypsinogen activation disturbing the intrapancreatic balance of proteases and their inhibitors. Other genes, such as the anionic trypsinogen (PRSS2), the serine protease inhibitor, Kazal type I (SPINK1) and the cystic fibrosis transmembrane conductance regulator (CFTR) have been found to be associated with chronic pancreatitis (idiopathic and hereditary) as well. Genetic testing should only be performed in carefully selected patients by direct DNA sequencing and antenatal diagnosis should not be encouraged. Treatment focuses on enzyme and nutritional supplementation, pain management, pancreatic diabetes, and local organ complications, such as pseudocysts, bile duct or duodenal obstruction. The disease course and prognosis of patients with HCP is unpredictable. Pancreatic cancer risk is elevated. Therefore, HCP patients should strongly avoid environmental risk factors for pancreatic cancer.

Disease name/synonyms

Hereditary chronic pancreatitis

Definition/diagnostic criteria

Genetic definition

Already in 1952 Comfort and Steinberg were first to recognize that chronic pancreatitis may accumulate in selected families suggesting a genetic background [1]. Thereafter, hereditary chronic pancreatitis (HCP) was

defined as an autosomal dominant disease with a penetrance of approximately 80%. However, in the daily clinical setting the inheritance pattern cannot be determined in some cases. In 1996 several groups mapped a gene for HCP to chromosome 7 [2-4]. In the same year, Whitcomb and colleagues identified an R122H mutation in the cationic trypsinogen gene (*PRSS1*) [5]. Several other mutations were described subsequently (A16V, D22G, K23R, N29I, N29T, R122C) [6-12]. Until now, the R122H and

N29I mutations of the *PRSS1* gene have been identified as the most common disease associated mutations [5-7].

In the last decade, several authors identified associations of chronic pancreatitis (idiopathic and hereditary) to other genes, such as the anionic trypsinogen (*PRSS2*), the Serine Protease Inhibitor, Kazal type 1 (*SPINK1*) and the cystic fibrosis transmembrane conductance regulator (*CFTR*) [13-16]. On the other hand, environmental factors as smoking, alcohol consumption or the lack of antioxidants were assumed to be important manifestation factors, even in HCP [17-20] (Figure 1).

The definition of HCP as a classic autosomal dominant disorder represents the current knowledge. However, the criteria of the diagnosis of HCP have been changing over the years and are currently different in the various clinical centres. In the recently published Europac study, the diagnosis of hereditary pancreatitis was made on the basis of two first-degree relatives or three or more second-degree relatives, in two or more generations with recurrent acute pancreatitis, and/or chronic pancreatitis for which there were no precipitating factors. Cases in which these strict criteria were not met, but more than one affected family member was identified, mostly within the same generation, were classified as familial chronic pancreatitis [21]. However, the diagnostic value of this classification is questionable. Therefore, we define HCP if the patient has no other detectable cause of chronic pancreatitis and if he/she has one first or second degree relative with proven

chronic pancreatitis. An international consensus is needed in the near future to classify affected families unambiguously.

Clinical definition and diagnostic criteria

Clinical definition

Chronic pancreatitis in adults is defined as a relapsing or continuing inflammatory disease of the pancreas characterized by irreversible morphological changes, upper abdominal pain and, in some patients, permanent impairment of exocrine function, endocrine function, or both [22]. The clinical course during an acute attack may range from mild edematous to severe necrotizing inflammation of the pancreas. The resulting morphological changes can be summarized as irregular sclerosis with focal, segmental, or diffuse destruction of the parenchyma. Frequently dilatations, strictures, or intraductal plugs can be seen in the pancreatic duct system. Initially, chronic pancreatitis is characterized by a recurrent stage of acute pancreatitis (early stage CP) passing over to progressive pancreatic dysfunction and/or pancreatic calcification (late stage CP).

Noteworthy in children the cardinal symptom is recurring, suddenly appearing epigastric pain. Contrary to adults, enduring pain is not a common clinical finding in children. Other symptoms are nausea, vomiting and abdominal pressure pain. Children partially develop pancreatic insufficiency with steatorrhoea and insulin-dependent diabetes, but these complications normally occur later than in patients with chronic alcoholic pancreatitis.




Figure 1
Diagrammatic illustration of genetic and environmental factors with their suspected influence on the pathogenesis of chronic pancreatitis. Abbreviations: ACP = alcoholic chronic pancreatitis, TCP = tropical calcific chronic pancreatitis, ICP = idiopathic chronic pancreatitis, HCP = hereditary chronic pancreatitis; abbreviations of the genes see within the text (According to Witt, [85]).

Diagnostic criteria

Diagnosis of chronic pancreatitis is made by clinical findings, a typical medical and family history, imaging methods and pancreatic function tests. The use of invasive function tests (secretin test, pancreozymin-secretin test) is declining over the last years. In recent reviews it was stated that invasive function tests in combination with pancreatic calcification are still the gold standard in the diagnosis of chronic pancreatitis, but these tests are laborious and costly [23-26]. Non-invasive tests (faecal chymotrypsin, PABA-, pancreolauryl- and faecal elastase test) are insufficient for the detection of minor or moderate insufficiency as a result of their restricted sensitivity compared to the pancreozymin-secretin test. As a consequence, function tests are of restricted value, particularly in early stage chronic pancreatitis [26,27]. A pragmatic and reasonable treatment is the supplementation of pancreatic enzymes *ex juvantibus* in patients with chronic pancreatitis and suspected exocrine insufficiency.

So far no imaging test has been established for the diagnosis of early stage chronic pancreatitis. In patients with late

stage chronic pancreatitis several imaging methods (ERCP, MR, MRCP, ES, CT, US, abdominal x-ray) are sufficient to detect typical morphological changes (e.g. duct alterations, calcification).

Epidemiology

There are no data regarding the incidence or prevalence of chronic hereditary pancreatitis or of chronic pancreatitis in children. The incidence of chronic pancreatitis of any cause is expected to be about 3.5–10 per 100.000 inhabitants and year in Europe and the USA [28,29].

Clinical description

Clinical characteristics

Alcoholic chronic pancreatitis and HCP exhibit essentially identical clinical laboratory results and histopathological or morphological features. Remarkably, HCP manifests typically at an earlier age and pancreatic calcification and diabetes mellitus are less frequent complications in comparison to chronic alcoholic pancreatitis. Certainly estimable is the fact that most investigated subjects with the N29I or R122H *PRSS1* mutation had mild disease or were asymptomatic [17,30].

Our investigations revealed no difference in the age of onset between carriers of these mutations. The median age of onset was 11 years in the N29I and 10 years in the R122H group, respectively. Only 4% of our patients had severe chronic pancreatitis with exocrine and endocrine insufficiency, pancreatic calcification and duct dilatation as well as hospitalizations due to pancreatitis. In general, half of the mutation carriers had little or no complaints or complications [17]. A European study revealed a mean age of onset of 10 years and 14.5 years for affected carriers of the *PRSS1* mutations R122H and N29I, respectively, but showed no mutation-dependent differences in complications such as exocrine or endocrine insufficiency or increased pancreatic cancer risk [21]. Data on the frequencies of acute pancreatitis attacks and pain in patients with HCP are not available to date. Chronic pancreatitis presents with a wide range of pain from mild to severe and from intermittent to persistent. Interestingly, endocrine insufficiency can regress over time, which is in contrast to current belief, that pancreatic diabetes is an irreversible sign of pancreatic failure [31]. However, prospective investigations of the course of diabetes in patients with HCP are lacking so far.

Hereditary chronic pancreatitis and pancreatic cancer

As shown in an investigation of 8 patients with pancreatic cancer in a cohort of 246 HCP patients, the lifetime risk of pancreatic cancer is about 50-fold higher than in the control population and corresponds with 1 per 1066 person-years. It is only 20-fold elevated in patients with chronic alcoholic pancreatitis [32,33]. In our cohort of 101 HCP

patients (25 N29I carrier, 76 R122H carrier), pancreatic cancer was diagnosed in 3 patients with the R122H mutation with a median of 23 years after the onset of pancreatitis. This corresponds to a rate of about 1 per 1200 person-years among affected R122H carriers [17]. Obviously, the data basis for the estimation of the pancreatic cancer risk in patients with *PRSS1* associated HCP is small. The largest clinical investigation in the pre-genetic era, however, revealed no pancreatic cancer in 72 patients from 7 families [19]. Taken together, the pancreatic cancer risk in HCP patients with a *PRSS1* mutation seems to be elevated – with an uncertain relative risk increase. Today, there is no generally accepted protocol for screening HCP patients for early pancreatic cancer. However, affected mutation carriers should be strongly advised to stop smoking, as it is an additional risk factor for pancreatic cancer [34].

Other genes associated to chronic pancreatitis

SPINK1 mutations in chronic pancreatitis

Witt and colleagues described at first an association between mutations of the serine protease inhibitor, Kazal type 1 (*SPINK1*) and chronic pancreatitis [14]. *SPINK1* is a potent protease inhibitor thought to be a specific inactivation factor of intrapancreatic trypsin activity. During incubation of equimolar quantities of trypsin and *SPINK1* the formation of a covalent bond between the catalytic serine residue of trypsin and the lysine carboxyl group of the reactive site of *SPINK1* is carried out. After prolonged incubation, trypsin activity reappears over time. This is explainable by the fact that *SPINK1* is degraded by trypsin [35]. The most frequently found *SPINK1* mutation is N34S. This mutation was predominantly found in patients with idiopathic chronic pancreatitis. Further investigations showed an association of *SPINK1* mutations and alcoholic chronic pancreatitis as well as tropical chronic pancreatitis [36-41]. Since 1–2% of controls carry the N34S mutation, this mutation alone seems to be insufficient to explain the pathogenesis of chronic pancreatitis in mutation carriers. Moreover, a functional analysis of recombinant *SPINK1* with the N34S mutation showed an unchanged function of N34S *SPINK1* as well as an unchanged trypsin susceptibility [42]. This indicates that mechanisms other than the conformational change of N34S might underlie the predisposition to chronic pancreatitis in mutation carriers.

CFTR mutations in chronic pancreatitis

Cystic fibrosis (*OMIM 219700*) is an autosomal recessive disorder with an incidence in whites of approximately 1 in 2500 live births. In 1989, *CFTR* (*OMIM 602421*) was identified as the underlying gene. In 1998, Sharer and colleagues and Cohn and colleagues were able to show an association of *CFTR* mutations with chronic pancreatitis [15,16]. This association is pathophysiologically compre-

hensible since 1–2% of patients with cystic fibrosis suffer from chronic pancreatitis [43,44]. The variety of pancreatic disorders in cystic fibrosis range from complete loss of exocrine and endocrine function to almost normal pancreatic function. So far more than 1500 mutations of the *CFTR* gene have been described [45]. According to their effect the mutations are split up in five or six classes (I-V/VI) [46,47]. In cystic fibrosis, the most common mutation is F508del, accounting for approximately 66% of all mutated alleles [48]. Interestingly, the clinical course of cystic fibrosis can be variable in patients carrying the same mutations, indicating the influence of environmental and maybe other genetic factors.

Recently published studies confirmed the association of chronic pancreatitis and *CFTR* mutations, but until now the underlying mechanisms leading to the development of chronic pancreatitis are poorly understood [49-54]. One of the main findings in all investigations is the detection of mostly rare *CFTR* mutations showing a different spectrum of detected mutations than in cystic fibrosis and congenital bilateral aplasia of the vas deferens (CBAVD). Some authors state that compound heterozygous *CFTR* carriers have a distinct elevated risk for the development of chronic pancreatitis, which is even higher when an additional *SPINK1* mutation is present [51,54].

However, the role of some *CFTR* mutations has to be reconsidered since Rohlf et al. demonstrated that the mutation I148T in Exon 4, which was classified as a severe cystic fibrosis causing mutation, is not associated to cystic fibrosis. According to their data the complex allele 3199del6 and I148T seems to be the relevant factor [55]. In summary, *CFTR* mutations alone are not sufficient for the pathogenesis of chronic pancreatitis in most patients and further studies are needed to elucidate the role of *CFTR* in the pathogenesis of chronic pancreatitis.

PRSS2 mutations in chronic pancreatitis

In an actual study of 2466 patients with chronic pancreatitis (including 1857 with hereditary or idiopathic pancreatitis) and 6459 controls by Witt et al., the G191R variant of the anionic trypsinogen was over represented in controls (32 vs. 220, odds ratio 0.37; $P = 1.1 \times 10^{-8}$). The analysis of the recombinantly expressed G191R variant revealed a complete loss of trypsin activity due to the introduction of a novel tryptic cleavage site that renders the enzyme hypersensitive to autocatalytic proteolysis. Taken together, the G191R variant of PRSS2 mitigates intrapancreatic trypsin activity and thereby plays a protective role against chronic pancreatitis [13]. This is the first study demonstrating a mutation with a protective effect in chronic pancreatitis.

Aetiologic and biochemical analysis of disease associated PRSS1 mutations

Classic HCP seems to follow an autosomal dominant inheritance with incomplete penetrance and highly variable disease expression. As stated above the results of research done within the last decade implicate a more complex inheritance pattern.

The *PRSS1* mutations are located in three clusters within the trypsinogen sequence: in the TAP (trypsinogen activation peptide), in the N-terminal part of trypsin or in the longest peptide segment not stabilized by disulfide bonds between Cys64 and Cys139 (Figure 2).

Thus, all pancreatitis associated *PRSS1* mutations discovered to date seem to cluster in the N-terminal half of the molecule encoded by exons 2 and 3. It is important to note, however, that investigation of the *PRSS1* gene in patients with suspected genetically determined chronic pancreatitis is restricted to these exons in most laboratories and possible C-terminal mutations may have been missed. The discovery of pancreatitis associated cationic trypsinogen mutations in 1996 demonstrated that trypsinogen plays a central role in the pathogenesis of human pancreatitis. These mutations seem to disturb the balance of proteases and their inhibitors within the pancreas leading to autodigestion of the organ (Figure 3).

The R122H and the N29I mutations are the most common *PRSS1* mutations worldwide. They have been frequently reported from Europe, North America and Asia [56] and R122H was also recently found in a family of






Figure 2

Linear map of pancreatitis associated mutations within the primary structure of the human cationic trypsinogen. The amino-acid positions affected by the pancreatitis-associated *PRSS1* mutations are denoted by asterisks (*). The positions of the most frequent N29I and R122H mutations are indicated. The blue call-out demonstrates the sequence of the trypsinogen activation peptide (TAP) and the mutations found in this region. The highly conserved tetra-aspartate motif in the activation peptide is underlined and bold.

normal pancreas



inherited pancreatitis

**Figure 3**

Model of inherited pancreatitis. In the normal pancreas (left) trypsin that is prematurely activated within the pancreas is inhibited by SPINK1 and in the second line by trypsin and mesotrypsin preventing autodigestion. In inherited pancreatitis (right) mutations in *PRSS1* or *SPINK1* lead to an imbalance of proteases and their inhibitors resulting in autodigestion. The role of CFTR is until now poorly understood. Abbreviations: AP = activation peptide (According to Witt, [85]).

Aboriginal descent in Australia [57]. Neither mutation was detected in two hereditary pancreatitis families from Brazil [58] and no hereditary pancreatitis cases have been reported from Africa. Here we summarize the most important genetic and biochemical data of the two common HCP associated *PRSS1* mutations N29I and R122H. These data are more extensively discussed in an actual review by our group [59].

R122H and increased trypsin stability

David Whitcomb proposed that the Arg122-Val123 autolytic peptide bond in trypsin plays an important role in the degradation of prematurely activated trypsin in the pancreas. Destruction of this "failsafe mechanism" by the R122H mutation would increase intrapancreatic trypsin activity and disturb the protease-antiprotease equilibrium and eventually provoke pancreatitis [5]. Biochemical evi-

dence supports the notion that Arg122 is important for autolysis of trypsin and mutations of this amino-acid result in increased trypsin stability [60-63]. A study using cerulein-induced zymogen activation in isolated rat acini demonstrated that autodegradation of trypsin mitigates cathepsin B-mediated trypsinogen activation, suggesting that a failsafe mechanism might be indeed operational in the mammalian pancreas [64]. The Whitcomb model in its original form has remained very popular over the years, even though more detailed biochemical analysis indicated that the R122H mutation results not only in increased trypsin stability but also in increased zymogen stability and increased autoactivation [62,63]. A weak trypsin-inhibitory activity associated with the Arg122 site is also lost in the R122H mutant [63]. Thus, the pleiotropic biochemical effect of R122H raises the possibility that the pathogenic alteration is unrelated to trypsin sta-

bility. More importantly, the model fails to explain how the other pancreatitis associated *PRSS1* mutations might work, as the majority of these do not affect trypsin stability.

N29I and enhanced trypsinogen autoactivation

Biochemical characterization of the N29I mutation using recombinant trypsinogen found no effect on trypsin or trypsinogen stability. On the other hand, two independent laboratories observed moderately increased autoactivation in 4 studies [62,65-67]. The N29T mutant, firstly described by Pfützner et al. in 2002, exhibited a phenotype similar to that of R122H, both increased trypsin stability and enhanced autoactivation were documented [11,64]. Because increased autoactivation was observed with the R122H, N29I and N29T mutations, whereas N29I had no effect on trypsin stability, the logical conclusion was put forth that enhanced autoactivation is the common pathogenic mechanism of hereditary pancreatitis associated *PRSS1* mutations [62].

Animal models

Genetically engineered animals offer the opportunity to study the effects of the foresaid mutations *in vivo*.

Transgenic expression of rat *SPINK1* in mice reduced the severity of experimental secretagogue-induced pancreatitis [68]. The transgenic animals had 190% increased endogenous trypsin inhibition capacity. Transgenic expression of *SPINK1* did not hinder trypsinogen activation, but reduced trypsin activity after supramaximal stimulation with cerulein. These *in vivo* results underline the hypothesis that enhanced inhibitory capacity of trypsin protects against pancreatitis.

Results from a mouse with targeted disruption of the pancreatic secretory trypsin inhibitor are puzzling [69]. A knockout (-/-) of the mouse homologue of human *SPINK1*, murine *Spink3*, is lethal within two weeks after birth. *Spink3* -/- embryos developed normally until day 15.5 after conception. Subsequently, autophagic degeneration of the pancreatic acinar cells started, interestingly without significant inflammatory cell infiltration. In this study, the authors were not able to detect enhanced trypsin activity in the acinar cells of the *SPINK* -/- animals. However, in a further study enhanced tryptic activity was found in pancreatic acini prepared one day after birth using a more sensitive assay [70]. Therefore, these data indicate that the total loss of *SPINK3* function leads to a strong imbalance in favour of trypsin activity resulting in acinar cell death and involution of the whole gland and finally leading to the lethal phenotype.

Two recent publications describe transgenic animals expressing R122H mutated trypsinogen [71,72]. Our

group developed a mouse expressing R122H human trypsinogen in the exocrine pancreas by using the rat elastase-2 promoter [71]. The animals showed slightly elevated serum levels of lipase without any significant histological alteration, suggesting a subtle acinar damage. After repetitive induction of experimental pancreatitis, pancreata of transgenic animals showed a higher inflammatory reaction than controls. The mild phenotype in these animals is probably caused by a low expression level of R122H mutated trypsinogen.

Transgenic expression of the R122H mutation of murine trypsin 4 in mouse pancreas led to progressive fibrosis and chronic inflammation of the pancreas [72]. Repetitive inductions of experimental pancreatitis with supramaximal doses of cerulein resulted in extensive deposition of collagen in peri-acinar and perilobular spaces of the transgenic animals. Thus, this animal model, which gives a significant expression level of R122H mutated trypsinogen, seems to recapitulate the human disease.

In summary, the animal studies indicate that disarranging the balance between trypsin and its inhibitors in favour of a higher intra-acinar tryptic activity contributes to the development of pancreatitis.

The trypsinogen und *SPINK1* mutation database

Since the first description of a trypsinogen mutation in hereditary pancreatitis, the experimental and clinical information on genetic alterations in chronic pancreatitis has been rapidly growing, resulting in a more and more complex data set. To address this issue, we implemented a continuously updated database in early 2001, which contains all genetic variants of the *PRSS* and *SPINK1* genes [73]. In addition to exact genetic data, this database contains links to the clinical characterization of patients with different mutations and to *in vitro* studies with mutant molecules.

Molecular diagnostic methods

The recommended "gold standard" method is direct DNA sequencing of both strands. Most laboratories have focused their studies on *PRSS1* exons 2 and 3, and until now no unambiguous disease associated mutation has been identified in the other exons. However, it is still possible that new variants will be identified in exons 1, 4 and 5, or in the intronic and promoter regions. Interestingly, the triplication of a segment containing the *PRSS1* gene was actually found in certain patients with HCP. This triplication seems to result in a gain of trypsin through a gene dosage effect and represents a previously unknown mechanism causing HCP [74].

There are several more methods to detect *PRSS1* mutations such as single strand conformation polymorphism

analysis (SSCP), restriction fragment length polymorphism analysis (RFLP) or denaturing high performance liquid chromatography (DHPLC). These methods are limited by a lack of sensitivity and specificity and since the nucleotide sequence is not detected subsequent sequencing of the altered probe is necessary in most cases. Above all Howes et al. showed that false negative results may be obtained regarding the R122H mutation, if RFLP is used with the restriction endonuclease *Afl III*, when a neutral polymorphism is present within the restriction site [75]. Melting curve analysis using fluorescence resonance energy transfer (FRET) probes is a highly efficient method with a very high sensitivity and specificity, however, only detecting the defined mutation and only partly other mutations located under the probes.

Therefore, since DNA sequencing has become more affordable within the last years and is also able to detect further mutations within the amplified fragment, sequencing of both strands should be performed.

Differential diagnosis

Well-recognized causative factors of chronic pancreatitis are anatomic anomalies, metabolic disorders, trauma, cystic fibrosis and inflammatory bowel disease. Since HCP manifests predominantly in childhood or early adulthood, alcohol abuse as the most common predisposing condition can nearly be ruled out. One of the most important differential diagnoses is cystic fibrosis. Therefore, all patients with onset of the disease in childhood and early adulthood should be screened for a pathological sweat chloride test and subsequently for the most common *CFTR* mutations of their population. Other rare differential diagnoses are hyperlipidaemia type I, familial (hypocalciuric) hypercalcaemia (FBH), hereditary hyperparathyroidism and autoimmune pancreatitis, last-mentioned usually manifesting in late adulthood [76-80].

Genetic counselling and testing

First of all, genetic counseling should be performed in an experienced multi-disciplinary clinic that can address the resulting issues. Before genetic testing is performed implications of finding HCP related mutations in the *PRSS1* gene for the health and the medical care of the patients should be discussed. Moreover, the elevated pancreatic cancer risk and the possible adverse effects for the patient regarding health and life insurance and employment should be brought up. Before performing the test, the form of communicating the test result should be assessed. Genetic testing should only be performed after informed consent.

The indication for *PRSS1* and *SPINK1* mutation testing in symptomatic patients should be one of the following:

1. recurrent unexplained attacks of acute pancreatitis and a positive family history
2. unexplained chronic pancreatitis and a positive family history
3. unexplained chronic pancreatitis without a positive family history after exclusion of other causes (see differential diagnoses)
4. unexplained pancreatitis episode in children

Noteworthy, genetic testing in children is a complex issue, since depending on their age children cannot always be included in the process of decision making whether genetic testing should be performed. Therefore, extensive genetic counseling, illuminating the above-mentioned aspects is necessary. Another important facet may be the information for anxious parents that genetic testing cannot predict the age of onset or the severity of the disease and that the findings of the analysis do not change the management of the disease today.

Beyond the hitherto discussed aspects the detection of *PRSS1* and *SPINK1* mutations will lead to a correct classification of the disease, helping the affected individual to better understand their disease and clearing out misclassifications (e.g. alcoholic chronic pancreatitis).

Predictive genetic testing should only be offered by a recognized service with adequate pre-test counselling, post-test support and clinical follow up. The persons capable of testing should have a first degree relative with a defined HCP gene mutation, should be able to understand the different above mentioned aspects and the request for genetic testing should have been consistently stated [81].

We want to emphasize anew that all HCP patients or potential *PRSS1* mutation carriers should be informed that the finding of a disease associated mutation does neither predict the onset or course of the disease nor affords specific diagnostic or therapeutic consequences.

Antenatal diagnosis

As the penetrance of inherited *PRSS1* mutations is incomplete, and a highly variable disease manifestation occurs within the most families, no antenatal diagnosis should be encouraged. Even in recently published guidelines concerning genetic testing in HCP the authors had reservations against antenatal diagnosis, but highlight that they cannot be so prescriptive as to refuse molecular genetic testing in an age of patient autonomy and informed consent [81]. Requesting parents should be informed, that even a painful course of the disease is self-limited to only

a few years in the most cases. No patient in our cohort find his life not lifeable due to disease-associated health limitations.

Management including treatment

No prospective randomised trial has been published for any medical or surgical problem in the management of HCP. Several case reports, but few systematic studies, address the medical and surgical treatment of HCP. Generally, the treatment does not differ from common forms of chronic pancreatitis.

In most instances treatment of chronic pancreatitis focuses on pain management, maldigestion, diabetes, pseudocysts, bile duct obstruction, duodenal obstruction and pancreatic cancer [27,82-84]. Regarding pain management amenable causes like pseudocysts, biliary and duodenal obstruction, and coincident peptic ulceration should be ruled out before an adequate pain therapy is started.

To stop the progression of the disease the consumption of alcohol should be an infrequent event, whereas smoking should be avoided completely. In concern of pancreatic insufficiency, frequent small meals with a low fat content may help to limit pancreatic stimulation while maintaining caloric intake. Maldigestion should be treated by supplementation of pancreatic enzymes in sufficient dosage. Management of endocrine failure is carried out according to the guidelines of approved diabetes societies.

A widely accepted indication for surgery in patients with HCP is chronic pain in the presence of a persistent dilatation of the main pancreatic duct. Many surgeons favour a longitudinal pancreaticojejunostomy (Puestow procedure modified by Partington and Rochelle) with good early results.

However, in patients without pancreatic duct dilatation, the operation seems not to be beneficial for the further course of pancreatitis or for the quality of life [85]. In addition, surgical interventions should be discussed with caution in children, as periods of only a few or even no symptoms frequently extend into adulthood. For these reasons, a decision to wait and see might be more appropriate than early operation in paediatric patients with HCP. In adults, surgical decisions on the basis of the guidelines concerning the indications for surgical treatment of patients with chronic pancreatitis of the more common underlying causes seem to be as effective in patients with HCP as in patients with chronic pancreatitis of other origins [86]. Unfortunately, there are no data regarding endoscopic procedures in the management of chronic pancreatitis patients. Therefore, prospective stud-

ies are needed to further elucidate the role of surgical and endoscopic management in chronic pancreatitis.

Prognosis

Today, the individual prognosis of HCP is unpredictable. It is neither possible to predict further episodes of acute pancreatitis, chronic bile duct obstruction, exocrine or endocrine pancreatic insufficiency nor the individual risk of pancreatic cancer.

Unresolved questions

From a genetic aspect, a more interesting quest in the near future will be for modifier genes that might explain the incomplete penetrance i.e. why some carriers of *PRSS1* mutations remain healthy, whereas their relatives with the same mutation exhibit severe disease. Despite intensive research, the disease mechanism remains poorly understood. The biochemical alterations caused by the mutations have been mostly clarified *in vitro*, but their phenotypic effect *in vivo* in most instances remains unclear. In this respect, future development of cellular and animal models of HCP will be particularly valuable.

Competing interests

The author(s) declare that they have no competing interests.

Note

Some parts of this work have been published in "Human Mutation" [59].

Acknowledgements

We gratefully acknowledge the helpful discussion with Professor Miklos Sahin-Tóth/Boston.

References

1. Comfort MW, Steinberg AG: **Pedigree of a family with hereditary chronic relapsing pancreatitis.** *Gastroenterology* 1952, **21**:54-63.
2. Whitcomb DC, Preston RA, Aston CE, et al.: **A gene for hereditary pancreatitis maps to chromosome 7q35.** *Gastroenterology* 1996, **110**:1975-1980.
3. Le Bodic L, Bignon JD, Raguénes O, et al.: **The hereditary pancreatitis gene maps to long arm of chromosome 7.** *Hum Mol Genet* 1996, **5**:549-554.
4. Pandya A, Blanton SH, Landa B, et al.: **Linkage studies in a large kindred with hereditary pancreatitis confirms mapping of the gene to a 16-cM region on 7q.** *Genomics* 1996, **38**:227-230.
5. Whitcomb DC, Gorry MC, Preston RA, et al.: **Hereditary pancreatitis is caused by a mutation in the cationic trypsinogen gene.** *Nat Genet* 1996, **14**:141-145.
6. Gorry MC, Ghabaizadeh D, Furey W, et al.: **Mutations in the cationic trypsinogen gene are associated with recurrent acute and chronic pancreatitis.** *Gastroenterology* 1997, **113**:1063-1068.
7. Teich N, Mössner J, Keim V: **Mutations of the cationic trypsinogen in hereditary pancreatitis.** *Hum Mutat* 1998, **12**:39-43.
8. Ferec C, Raguénes O, Salomon R, et al.: **Mutations in the cationic trypsinogen gene and evidence for genetic heterogeneity in hereditary pancreatitis.** *J Med Genet* 1999, **36**:228-232.
9. Witt H, Luck W, Becker M: **A signal peptide cleavage site mutation in the cationic trypsinogen gene is strongly associated with chronic pancreatitis.** *Gastroenterology* 1999, **117**:7-10.

10. Le Maréchal C, Chen JM, Quere I, et al.: **Discrimination of three mutational events that result in a disruption of the R122 primary autolysis site of the human cationic trypsinogen (PRSSI) by denaturing high performance liquid chromatography.** *BMC Genet* 2001, **2**:19.
11. Pfützer RH, Myers E, Applebaum-Shapiro S, et al.: **Novel cationic trypsinogen (PRSSI) N29T and R122C mutations cause autosomal dominant hereditary pancreatitis.** *Gut* 2002, **50**:271-272.
12. Simon P, Weiss FU, Sahin-Tóth M, et al.: **Hereditary pancreatitis caused by a novel PRSSI mutation (Arg-122 --> Cys) that alters autoactivation and autodegradation of cationic trypsinogen.** *J Biol Chem* 2002, **277**:5404-5410.
13. Witt H, Sahin-Tóth M, Landt O, et al.: **A degradation-sensitive anionic trypsinogen (PRSS2) variant protects against chronic pancreatitis.** *Nat Genet* 2006, **38**:668-673.
14. Witt H, Luck W, Hennies HC, et al.: **Mutations in the gene encoding the serine protease inhibitor, Kazal type I are associated with chronic pancreatitis.** *Nat Genet* 2000, **25**:213-216.
15. Sharer N, Schwartz M, Malone G, et al.: **Mutations of the cystic fibrosis gene in patients with chronic pancreatitis.** *New Engl J Med* 1998, **339**:645-652.
16. Cohn JA, Friedman KJ, Noone PG, et al.: **Relation between mutations of the cystic fibrosis gene and idiopathic pancreatitis.** *New Engl J Med* 1998, **339**:653-658.
17. Keim V, Bauer N, Teich N, et al.: **Clinical characterization of patients with hereditary pancreatitis and mutations in the cationic trypsinogen gene.** *Am J Med* 2001, **111**:622-626.
18. Sossenheimer MJ, Aston CE, Preston RA, et al.: **Clinical characteristics of hereditary pancreatitis in a large family, based on high-risk haplotype. The Midwest Multicenter Pancreatic Study Group (MMPSTG).** *Am J Gastroenterol* 1997, **92**:1113-1116.
19. Sibert JR: **Hereditary pancreatitis in England and Wales.** *J Med Genet* 1978, **15**:189-201.
20. Amann ST, Gates LK, Aston CE, et al.: **Expression and penetrance of the hereditary pancreatitis phenotype in monozygotic twins.** *Gut* 2001, **48**:542-547.
21. Howes N, Lerch MM, Greenhalf W, et al.: **European Registry of Hereditary Pancreatitis and Pancreatic Cancer (EUROPAC). Clinical and genetic characteristics of hereditary pancreatitis in Europe.** *Clin Gastroenterol Hepatol* 2004, **2**:252-261.
22. Singer MV, Gyr K, Sarles H: **Report of the Second International Symposium on the Classification of Pancreatitis in Marseille, France, March 28-30, 1984.** *Gastroenterology* 1985, **89**:683-685.
23. Boeck WG, Adler G, Gress TM: **Pancreatic function tests: When to choose, what to use.** *Current Gastroenterol Rep* 2001, **3**:95-100.
24. Choudhury RS, Forsmark E: **Review article: pancreatic function testing.** *Aliment Pharmacol Ther* 2003, **17**:733-750.
25. Siegmund E, Löhr JM, Schuff-Werner P: **Die diagnostische Validität nicht-invasiver Pankreasfunktionstests – eine Metaanalyse.** *Z Gastroenterol* 2004, **42**:1117-1128.
26. Ammann RW: **Diagnosis and management of chronic pancreatitis: current knowledge.** *Swiss Med Wkly* 2006, **136**:166-174.
27. Etemad B, Whitcomb DC: **Chronic pancreatitis: diagnosis, classification, and new genetic developments.** *Gastroenterology* 2001, **120**:682-707.
28. Andersen BN, Pedersen NT, Scheel J, et al.: **Incidence of alcoholic chronic pancreatitis in Copenhagen.** *Scand J Gastroenterol* 1982, **17**:247-252.
29. Barkin JS, Fayne SD: **Chronic pancreatitis: update 1986.** *Mt Sinai J Med* 1986, **53**:404-408.
30. Keim V, Witt H, Bauer N, et al.: **The course of genetically determined chronic pancreatitis.** *J Pancreas (Online)* 2003, **4**:146-154.
31. Uhlig HH, Galler A, Keim V, et al.: **Regression of pancreatic diabetes in chronic hereditary pancreatitis.** *Diabetes Care* 2006, **29**:1981-1982.
32. Lowenfels AB, Maisonneuve P, Di Magno EP, et al.: **Hereditary pancreatitis and the risk of pancreatic cancer. International Hereditary Pancreatitis Study Group.** *J Natl Cancer Inst* 1997, **89**:442-446.
33. Malka D, Hammel P, Maire F, et al.: **Risk of pancreatic adenocarcinoma in chronic pancreatitis.** *Gut* 2002, **51**:849-852.
34. Lowenfels AB, Maisonneuve P, Whitcomb DC: **Risk factors for cancer in hereditary pancreatitis. International Hereditary Pancreatitis Study Group.** *Med Clin North Am* 2000, **84**:565-573.
35. Laskowski M, Wu FC: **Temporary inhibition of trypsin.** *J Biol Chem* 1953, **204**:797-805.
36. Witt H, Luck W, Becker M, et al.: **Mutation in the SPINK1 trypsin inhibitor gene, alcohol use, and chronic pancreatitis.** *JAMA* 2001, **285**:2716-2717.
37. Drenth JP, te Morsche R, Jansen JB: **Mutations in serine protease inhibitor Kazal type I are strongly associated with chronic pancreatitis.** *Gut* 2002, **50**:687-692.
38. Chandak GR, Idris MM, Reddy DN, et al.: **Mutations in the pancreatic secretory trypsin inhibitor gene (PSTI/SPINK1) rather than the cationic trypsinogen gene (PRSSI) are significantly associated with tropical calcific pancreatitis.** *J Med Genet* 2002, **39**:347-351.
39. Hassan Z, Mohan V, Ali L, et al.: **SPINK1 is a susceptibility gene for fibrocalculous pancreatic diabetes in subjects from the Indian subcontinent.** *Am J Hum Genet* 2002, **71**:964-968.
40. Bhatia E, Choudhuri G, Sikora SS, et al.: **Tropical calcific pancreatitis: strong association with SPINK1 trypsin inhibitor mutations.** *Gastroenterology* 2002, **123**:1020-1025.
41. Schneider A, Suman A, Rossi L, et al.: **SPINK1/PSTI mutations are associated with tropical pancreatitis and type II diabetes mellitus in Bangladesh.** *Gastroenterology* 2002, **123**:1026-1030.
42. Kuwata K, Hirota M, Shimizu H, et al.: **Functional analysis of recombinant pancreatic secretory trypsin inhibitor protein with amino-acid substitution.** *J Gastroenterol* 2002, **37**:928-934.
43. Shwachman H, Lebenthal E, Khaw W: **Recurrent acute pancreatitis in patients with cystic fibrosis with normal pancreatic enzymes.** *Pediatrics* 1975, **55**:86-94.
44. Atlas AB, Orenstein SR, Orenstein DM: **Pancreatitis in young children with cystic fibrosis.** *J Pediatr* 1992, **120**:756-759.
45. **Cystic Fibrosis Mutation Database** [<http://www.genet.sickkids.on.ca/cftr/>]
46. Welsh M, Smith A: **Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis.** *Cell* 1993, **73**:1251-1254.
47. Wilschanski M, Zielenski J, Markiewicz D, et al.: **Correlation of sweat chloride concentration with classes of the cystic fibrosis transmembrane conductance regulator gene mutations.** *J Pediatr* 1995, **127**:705-710.
48. The Cystic Fibrosis Genetic Analysis Consortium: **Population variation of common cystic fibrosis mutations.** *Hum Mutat* 1994, **4**:167-177.
49. Castellani C, Bonizzato A, Rolfini R, et al.: **Increased prevalence of mutations of the cystic fibrosis gene in idiopathic chronic and recurrent pancreatitis (letter).** *Am J Gastroenterol* 1999, **94**:1993-1995.
50. Castellani C, Gomez Lira M, Frulloni L, et al.: **Analysis of the entire coding region of the cystic fibrosis transmembrane regulator gene in idiopathic pancreatitis.** *Hum Mutat* 2001, **18**:166.
51. Noone PG, Zhou Z, Silverman LM, et al.: **Cystic fibrosis gene mutations and pancreatitis risk: relation to epithelial ion transport and trypsin inhibitor gene mutations.** *Gastroenterology* 2001, **121**:1310-1319.
52. Audrézet MP, Chen JM, Le Maréchal C, et al.: **Determination of the relative contribution of three genes-the cystic fibrosis transmembrane conductance regulator gene, the cationic trypsinogen gene, and the pancreatic secretory trypsin inhibitor gene-to the etiology of idiopathic chronic pancreatitis.** *Eur J Hum Genet* 2002, **10**:100-106.
53. Weiss FU, Simon P, Bogdanova N, et al.: **Complete cystic fibrosis transmembrane conductance regulator gene sequencing in patients with idiopathic chronic pancreatitis and controls.** *Gut* 2005, **54**:1456-1460.
54. Cohn JA, Neoptolemos JP, Feng J, et al.: **Increased risk of idiopathic chronic pancreatitis in cystic fibrosis carriers.** *Hum Mutat* 2005, **26**:303-307.
55. Rohlfes EM, Zhou Z, Sugarman , et al.: **The I148T CFTR allele occurs on multiple haplotypes: a complex allele is associated with cystic fibrosis.** *Genet Med* 2002, **4**:319-323.
56. Nishimori I, Kamakura M, Fujikawa-Adachi K, et al.: **Mutations in exons 2 and 3 of the cationic trypsinogen gene in Japanese families with hereditary pancreatitis.** *Gut* 1999, **44**:259-263.
57. McLaughran JM, Kimble R, Upton J, et al.: **Hereditary pancreatitis in a family of Aboriginal descent.** *J Paediatr Child Health* 2004, **40**:487-489.

58. Bernardino AL, Guarita DR, Mott CB, et al.: **CFTR, PRSSI and SPINK1 mutations in the development of pancreatitis in Brazilian patients.** *J Pancreas (Online)* 2003, **4**:169-177.
59. Teich N, Rosendahl J, Tóth M, et al.: **Mutations of human cationic trypsinogen and chronic pancreatitis.** *Hum Mutat* 2006, **27**:721-730.
60. Higaki JN, Light A: **Independent refolding of domains in the pancreatic serine proteinases.** *J Biol Chem* 1986, **261**:10606-10609.
61. Gaboriaud C, Serre L, Guy-Crotte O, et al.: **Crystal structure of human trypsin I: unexpected phosphorylation of Tyr151.** *J Mol Biol* 1996, **259**:995-1010.
62. Sahin-Tóth M, Tóth M: **Gain-of-function mutations associated with hereditary pancreatitis enhance autoactivation of human cationic trypsinogen.** *Biochem Biophys Res Commun* 2000, **278**:286-289.
63. Kukor Z, Tóth M, Pál G, et al.: **Human cationic trypsinogen. Arg(117) is the reactive site of an inhibitory surface loop that controls spontaneous zymogen activation.** *J Biol Chem* 2002, **277**:6111-6117.
64. Halangk MW, Lerch MM, Brandt-Nedelev B, et al.: **Role of cathepsin B in intracellular trypsinogen activation and the onset of acute pancreatitis.** *J Clin Invest* 2000, **106**:773-781.
65. Sahin-Tóth M: **Human cationic trypsinogen. Role of Asn-21 in zymogen activation and implications in hereditary pancreatitis.** *J Biol Chem* 2000, **275**:22750-22755.
66. Szilágyi L, Kénesi E, Katona G, et al.: **Comparative in vitro studies on native and recombinant human cationic trypsins. Cathepsin B is a possible pathological activator of trypsinogen in pancreatitis.** *J Biol Chem* 2001, **276**:24574-24580.
67. Teich N, Nemoda Z, Köhler H, et al.: **Gene conversion between functional trypsinogen genes PRSSI and PRSS2 associated with chronic pancreatitis in a six-year-old girl.** *Hum Mutat* 2005, **25**:343-347.
68. Nathan JD, Romac J, Peng RY, et al.: **Transgenic expression of pancreatic secretory trypsin inhibitor-I ameliorates secretagogue-induced pancreatitis in mice.** *Gastroenterology* 2005, **128**:717-727.
69. Ohmuraya M, Hirota M, Araki M, et al.: **Autophagic cell death of pancreatic acinar cells in serine protease inhibitor Kazal type 3-deficient mice.** *Gastroenterology* 2005, **129**:696-705.
70. Ohmuraya M, Hirota M, Araki K, et al.: **Enhanced trypsin activity in pancreatic acinar cells deficient for serine protease inhibitor kazal type 3.** *Pancreas* 2006, **33**:104-106.
71. Selig L, Sack U, Gaiser S, et al.: **Characterisation of a transgenic mouse expressing R122H human cationic trypsinogen.** *BMC Gastroenterology* 2006, **6**:30.
72. Archer H, Jura N, Keller J, Jacobson M, et al.: **A Mouse Model of Hereditary Pancreatitis Generated by Transgenic Expression of R122H Trypsinogen.** *Gastroenterology* 2006, **131**:1844-1855.
73. **Database of Genetic Variants in Patients with Chronic Pancreatitis** [<http://www.uni-leipzig.de/pancreasmutation>]
74. Le Maréchal C, Masson E, Chen JM, et al.: **Hereditary pancreatitis caused by triplication of the trypsinogen locus.** *Nat Genet* 2006, **38**:1372-1374.
75. Howes N, Greenhalf W, Rutherford S, et al.: **A new polymorphism for the R122H mutation in hereditary pancreatitis.** *Gut* 2001, **48**:247-250.
76. Wilson DE: **Mutations in exon 3 of the lipoprotein lipase gene segregating in a family with hypertriglyceridemia, pancreatitis, and non-insulin-dependent diabetes.** *J Clin Invest* 1993, **92**:203-211.
77. Trump D, Whyte MP, Wooding C, et al.: **Linkage studies in a kindred from Oklahoma, with familial benign (hypocalciuric) hypercalcaemia (FBH) and developmental elevations in serum parathyroid hormone levels, indicate a third locus for FBH.** *Hum Genet* 1995, **96**:183-187.
78. Jackson CE: **Hereditary hyperparathyroidism associated with recurrent pancreatitis.** *Ann Intern Med* 1958, **49**:829-836.
79. Kamisawa T, Egawa N, Nakajima H, et al.: **Clinical difficulties in the differentiation of autoimmune pancreatitis and pancreatic carcinoma.** *Am J Gastroenterol* 2003, **98**:2694-2699.
80. Sarles H, Sarles JC, Muratore R, et al.: **Chronic inflammatory sclerosis of the pancreas: an autoimmune pancreatic disease?** *Am J Dig Dis* 1961, **6**:688-698.
81. Ellis I, Lerch MM, Whitcomb DC: **Genetic testing for hereditary pancreatitis: Guidelines for indications, counselling, consent and privacy issues.** *Pancreatology* 2001, **1**:405-415.
82. Lankisch PG, Lohr-Happe A, Otto J, et al.: **Natural course in chronic pancreatitis. Pain, exocrine and endocrine pancreatic insufficiency and prognosis of the disease.** *Digestion* 1993, **54**:148-155.
83. Lankisch PG, Seidensticker F, Lohr-Happe A, et al.: **The course of pain is the same in alcohol- and non-alcohol-induced chronic pancreatitis.** *Pancreas* 1995, **10**:338-341.
84. Layer P, Yamamoto H, Kalthoff L, et al.: **The different courses of early- and late-onset idiopathic and alcoholic chronic pancreatitis.** *Gastroenterology* 1994, **107**:1481-1487.
85. Moir CR, Konzen KM, Perrault J: **Surgical therapy and longterm follow-up of childhood hereditary pancreatitis.** *J Pediatr Surg* 1992, **27**:282-286.
86. Miller AR, Nagorney DM, Sarr MG: **The surgical spectrum of hereditary pancreatitis in adults.** *Ann Surg* 1992, **215**:39-43.
87. Witt H: **Chronic pancreatitis and cystic fibrosis.** *Gut* 2003, **52**(Suppl II):ii34-ii41.

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp

